Steven L. Groopman
Partner
Steven L. Groopman is a partner in the Boston office of Berman Tabacco. Steve seeks to use the law in a compelling and creative manner to achieve financial justice for clients in the healthcare industry. He currently litigates cutting-edge antitrust, consumer, and corporate governance matters.
Prior to joining the firm in 2015, Steve served as a law clerk to the Hon. Dickinson R. Debevoise on the U.S. District Court for the District of New Jersey. Earlier in his career, Steve worked as an associate at a litigation and white-collar defense boutique law firm in New York.
During law school, Steve interned at the World Organization for Human Rights and with the Hon. Nicholas G. Garaufis on the U.S. District Court for the Eastern District of New York. He also served as a Student-Attorney in his law school’s appellate defender clinic. Before law school, he worked as a Reporter-Researcher at The New Republic magazine in Washington, D.C.
Steve was ranked by Benchmark Litigation as a Massachusetts Future Star (2025) and he was previously recognized by Benchmark Litigation in its 40 & Under List in Plaintiff Class Action (2022-2023). He has also been ranked by New England/Massachusetts Super Lawyers as a Super Lawyer (2023-2024) and previously as a Rising Star (2017-2022).
Experience
- Currently representing a proposed class of third-party payors in Iron Workers District Council of New England Health and Welfare Fund v. Teva Pharmaceutical Industries Ltd., No. 1:23-cv-11131 (D. Mass.), alleging alleging that defendant Teva and its affiliates, embarked on a nearly decade-long (and continuing) anticompetitive scheme to delay generic competition for QVAR, its blockbuster line of brand-name asthma inhalers.
- Currently representing a proposed class of airline ticket purchasers in In re American Airlines/Jetblue Antitrust Litigation, No. 1:22-cv-07374-AMD-TAM (E.D.N.Y.), alleging that American Airlines and JetBlue entered into an agreement to collude, rather than compete, for customers at four Northeast airports, driving up airline ticket prices.
- Currently representing an institutional shareholder of Centene Corporation in Bricklayers Pension Fund of Western Pennsylvania v. Brinkley, et al., No. 2022-1118-MTZ (Del. Ch.), alleging that Centene’s Board of Directors failed to oversee compliance in connection with Medicaid cost reporting, resulting in a massive Medicaid fraud.
- Previously represented a proposed class of EpiPen purchasers in Klein, et al. v. Prime Therapeutics, LLC, at al., No. 17-cv-1884 (D. Minn.) and Illis Optum Inc., et al., No. 17-cv-5154 (D. Minn.), alleging that major pharmacy benefit managers violated the Employee Retirement Income Security Act (ERISA) by extracting rebates and other monies from Mylan N.V., keeping a significant amount of those monies for themselves, and causing Mylan to raise EpiPen’s list price that the class is subject to under the terms of their ERISA health plans.
- Previously represented a proposed class of consumer borrowers in Gingras, et al. v. Rosette, et al., No. 15-cv-0101 (D. Vt.), alleging that online payday lenders, along with a major hedge fund and venture capitalists, engaged in a scheme to defraud and to collect unlawful debt, in violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), by creating and controlling a Native American tribal entity and issuing usurious loans through that entity in an effort to circumvent state and federal law.
- Previously represented a proposed class of consumer borrowers in Solomon, et al. v. American Web Loan, Inc., et al., No. 17-cv-0145 (E.D. Va.), alleging that online payday lenders and a private equity firm engaged in unlawful debt collection, in violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), by issuing usurious loans through a Native American tribal entity in an effort to circumvent state and federal law, and in violation of the Truth In Lending Act (TILA), for the failure to inform consumer borrowers of material terms of their loans during the application process.
Publications, Presentations & Appearances
- A View from the Courthouse: Lawsuits Targeting PBMs, Coalition of State Rheumatology Organizations, 2017 State Society Advocacy Conference, September 9, 2017
- Why Dark Money is Bad Business, The New York Times, May 10, 2016
Steven L. Groopman is a partner in the Boston office of Berman Tabacco. Steve seeks to use the law in a compelling and creative manner to achieve financial justice for clients in the healthcare industry. He currently litigates cutting-edge antitrust, consumer, and corporate governance matters.
Prior to joining the firm in 2015, Steve served as a law clerk to the Hon. Dickinson R. Debevoise on the U.S. District Court for the District of New Jersey. Earlier in his career, Steve worked as an associate at a litigation and white-collar defense boutique law firm in New York.
During law school, Steve interned at the World Organization for Human Rights and with the Hon. Nicholas G. Garaufis on the U.S. District Court for the Eastern District of New York. He also served as a Student-Attorney in his law school’s appellate defender clinic. Before law school, he worked as a Reporter-Researcher at The New Republic magazine in Washington, D.C.
Steve was ranked by Benchmark Litigation as a Massachusetts Future Star (2025) and he was previously recognized by Benchmark Litigation in its 40 & Under List in Plaintiff Class Action (2022-2023). He has also been ranked by New England/Massachusetts Super Lawyers as a Super Lawyer (2023-2024) and previously as a Rising Star (2017-2022).
Education
- George Washington University Law School (J.D., 2009)
- Brown University (A.B., Magna Cum Laude, Political Science, 2005)
Experience
- Currently representing a proposed class of third-party payors in Iron Workers District Council of New England Health and Welfare Fund v. Teva Pharmaceutical Industries Ltd., No. 1:23-cv-11131 (D. Mass.), alleging alleging that defendant Teva and its affiliates, embarked on a nearly decade-long (and continuing) anticompetitive scheme to delay generic competition for QVAR, its blockbuster line of brand-name asthma inhalers.
- Currently representing a proposed class of airline ticket purchasers in In re American Airlines/Jetblue Antitrust Litigation, No. 1:22-cv-07374-AMD-TAM (E.D.N.Y.), alleging that American Airlines and JetBlue entered into an agreement to collude, rather than compete, for customers at four Northeast airports, driving up airline ticket prices.
- Currently representing an institutional shareholder of Centene Corporation in Bricklayers Pension Fund of Western Pennsylvania v. Brinkley, et al., No. 2022-1118-MTZ (Del. Ch.), alleging that Centene’s Board of Directors failed to oversee compliance in connection with Medicaid cost reporting, resulting in a massive Medicaid fraud.
- Previously represented a proposed class of EpiPen purchasers in Klein, et al. v. Prime Therapeutics, LLC, at al., No. 17-cv-1884 (D. Minn.) and Illis Optum Inc., et al., No. 17-cv-5154 (D. Minn.), alleging that major pharmacy benefit managers violated the Employee Retirement Income Security Act (ERISA) by extracting rebates and other monies from Mylan N.V., keeping a significant amount of those monies for themselves, and causing Mylan to raise EpiPen’s list price that the class is subject to under the terms of their ERISA health plans.
- Previously represented a proposed class of consumer borrowers in Gingras, et al. v. Rosette, et al., No. 15-cv-0101 (D. Vt.), alleging that online payday lenders, along with a major hedge fund and venture capitalists, engaged in a scheme to defraud and to collect unlawful debt, in violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), by creating and controlling a Native American tribal entity and issuing usurious loans through that entity in an effort to circumvent state and federal law.
- Previously represented a proposed class of consumer borrowers in Solomon, et al. v. American Web Loan, Inc., et al., No. 17-cv-0145 (E.D. Va.), alleging that online payday lenders and a private equity firm engaged in unlawful debt collection, in violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), by issuing usurious loans through a Native American tribal entity in an effort to circumvent state and federal law, and in violation of the Truth In Lending Act (TILA), for the failure to inform consumer borrowers of material terms of their loans during the application process.
Honors & Distinctions
- Ranked by Benchmark Litigation as a Massachusetts Future Star (2025)
- Recognized by Benchmark Litigation in its 40 & Under List in Plaintiff Class Action (2022-2023)
- Named a Super Lawyer by Massachusetts Super Lawyers (2023-2024)
- Named a Rising Star by New England/Massachusetts Super Lawyers (2017-2022)
Admissions
- State Bar of Massachusetts
- State Bar of New York
- U.S. District Court for the District of Massachusetts
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of New York
- U.S. Court of Appeals for the Second Circuit
- U.S. Court of Appeals for the Fourth Circuit
Affiliations
- The Corporate Reform Coalition (Public Citizen)
Publications, Presentations & Appearances
- A View from the Courthouse: Lawsuits Targeting PBMs, Coalition of State Rheumatology Organizations, 2017 State Society Advocacy Conference, September 9, 2017
- Why Dark Money is Bad Business, The New York Times, May 10, 2016